NeutraControl IL-17A Monoklonaler Antikörper

NeutraControl IL-17A Monoklonal Antikörper für Non-Neutralization, ELISA

Wirt / Isotyp

Maus / IgG1

Getestete Reaktivität

human

Anwendung

Non-Neutralization

Konjugation

Unkonjugiert

CloneNo.

2A7E2

Kat-Nr. : 69521-1-Ig

Synonyme

CTLA 8, CTLA8, IL 17, IL 17A, IL17, IL17A, IL-17A, interleukin 17A



Produktinformation

69521-1-Ig bindet in Non-Neutralization IL-17A und zeigt Reaktivität mit human

Getestete Reaktivität human
Wirt / Isotyp Maus / IgG1
Klonalität Monoklonal
Typ Antikörper
Immunogen human Humankine IL-17A protein HZ-1113
Vollständiger Name interleukin 17A
Gene symbol IL17A
Gene ID (NCBI) 3605
Konjugation Unkonjugiert
Form Lyophilized Powder
Reinigungsmethode Protein-G-Reinigung
Lagerungspuffer Sterile PBS.
Endotoxin<0.1 EU/μg
WiederherstellungThis product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use.
Stability and StorageLyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.

Hintergrundinformationen

IL17A, also named as IL-17, is a proinflammatory cytokine. IL-17, synthesized only by memory T cells and natural killer cells, has pleiotropic effects, mainly in the recruitment and activation of neutrophils. This cytokine regulates the activities of NF-kappaB and mitogen-activated protein kinases. This cytokine can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO). High levels of this cytokine are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis. The IL-17 receptor is a type I transmembrane protein, that is widely expressed on epithelial cells, fibroblasts, B and T cells, and monocytic cells. In psoriatic skin lesions, both Th17 cells and their downstream effector molecules, e.g. IL-17 and IL-22, are highly increased.

This antibody is a neutralizing control antibody for IL-17A, the immunogen is the same as Neutrakine 69021-1-Ig but could not neutralize human IL-17A.